Amid the growing popularity of aesthetic and anti-aging procedures in India, the government has clarified that injectable products such as Botox, dermal fillers, and similar “beauty injections” cannot be classified or sold as cosmetics. The move comes as authorities tighten scrutiny over the rapidly expanding
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations With its debut registration of Sugammadex in Philippines, Venus Remedies strengthens its foothold in the ASEAN market Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian manufacturer
Gland Pharma Limited (BSE: 543245 I NSE: GLAND), a generic injectable-focused pharmaceutical company, today announced its financial results for the Second quarter (Q2FY25) ended on September 30th, 2024. Financial Highlights Q2 FY25 (July 2024 to September 2024) • Consolidated revenue increased 2% year-over-year to INR 14,058 million. • Consolidated EBITDA decreased
OneSource Specialty Pharma, a newly formed CDMO, is formed from the merger of three CDMO businesses within the Strides Group, which boasts a 30-year track-record of excellence in manufacturing and quality. The company is launching its new brand identity with a strong emphasis on customer
Eris Lifesciences Ltd., a leading Indian branded formulations company, today announced the expansion of its Sterile Injectables footprint through the acquisition of 51% equity stake in Swiss Parenterals Ltd. for a consideration of INR 637.50 crore. This deal also marks the entry of Eris into
This GMP certification for the company’s production facilities has added to its portfolio of international approvals from 25 regulators The recognition demonstrates Venus Remedies’ persistence in adhering to stringent manufacturing standards and providing greater access to life-saving drugs in the African continent Venus Remedies, a
